AccurEdit Therapeutics

Executive Summary

AccurEdit Therapeutics is a Shanghai-based biotechnology company pioneering in vivo CRISPR gene editing therapies for severe hereditary and acquired diseases. Founded in 2021, the company has built a proprietary end-to-end platform encompassing RNA synthesis, novel base editors and Cas enzymes, and targeted delivery technologies. By focusing on precise genetic modification directly in the body, AccurEdit aims to provide durable, potentially curative treatments for conditions with high unmet need, such as transthyretin amyloidosis (ATTR) and cardiovascular disorders. The company is privately held and has advanced its lead candidate, ART001, into Phase 1 clinical development, leveraging its differentiated editing and delivery capabilities. ART001 targets ATTR amyloidosis, a progressive, life-threatening disease caused by misfolded transthyretin protein. Early clinical data have shown promising safety and preliminary efficacy, supporting the potential of in vivo gene editing to address the root cause of the disease. With a strong intellectual property estate and a growing pipeline, AccurEdit is positioned to contribute to the next wave of genetic medicines. Upcoming catalysts include the release of additional Phase 1 data, expansion into new indications, and potential strategic partnerships to accelerate development and commercialization.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data update for ART001 in ATTR amyloidosis70% success
• Q4 2026IND / CTA submission for a second pipeline candidate (e.g., cardiovascular indication)50% success
• H1 2027Announcement of a licensing or collaboration deal with a major pharma40% success